Seemingly complete removal of histologically benign intracranial meningioma: Late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis

doi:10.1016/0090-3019(86)90259-4

Surgical Neurology

Volume 26, Issue 5, November 1986, Pages 461-469

https://doi.org/10.1016/0090-3019(86)90259-4 Get rights and content

Abstract

From 1953 to 1980, 657 patients survived a seemingly complete removal of a histologically benign intracranial meningioma. Recurrence of the tumor was found in 59 of these 657 patients, but some cases of recurrence may have been missed inasmuch as only 69 patients were followed for 20 years. With ordinary life-table analysis, the overall recurrence rate was estimated to be 19% at 20 years. The reliability of this result was evaluated with a modified life-table analysis. Multivariate analysis showed that coagulation of the dural insertion, invasion of bone, and soft consistency of tumor were strong risk factors (p < 0.01) for recurrence. The recurrence rate at 20 years was estimated to be 11% for the 249 patients with none of these risk factors, 15–24% for those with one factor, and 34–56% for those with two.

References (27)

J Jääskeläinen et al.
Intracranial hemangiopericytoma: radiology, surgery, radiotherapy and outcome in 21 patients
Surg Neurol
(1985)
J Jääskeläinen et al.
The growth rate of intracranial meningioma and its relation to histology: an analysis of 43 patients
Surg Neurol
(1985)
J Jääskeläinen et al.
Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy and outcome
Surg Neurol
(1986)
AB Adegbite et al.
The recurrence of intracranial meningiomas after surgical treatment
J Neurosurg
(1983)
OT Bailey
Histological sequences in the meningioma, with a consideration of the nature of the hyperostosis cranii
Arch pathol
(1940)
J Bonnal et al.
Invading meningiomas of the sphenoid ridge
J Neurosurg
(1980)
RC Chan et al.
Morbidity, mortality, and quality of life following surgery for intracranial meningiomas
CL Chiang
Introduction to stochastic processes in biostatistics
(1968)
D Christensen et al.
Prediction of recurrence in meningiomas after surgical treatment
Acta Neuropathol (Berl)
(1983)
H Cushing et al.
Meningiomas, their classification, regional behavior, life history, and end surgical results
(1938)

SJ Cutler et al.

Maximum utilization of the life-table method in analyzing survival

J Chron Dis

(1958)

H Freedman et al.

Bone formation and destruction in hyperostoses associated with meningiomas

J Neuropathol Exp Neurol

(1948)

Cited by (443)

Preoperative Prediction of Meningioma Subtype by Constructing a Clinical-Radiomics Model Nomogram Based on Magnetic Resonance Imaging
2024, World Neurosurgery
We sought to investigate the value of a clinical-radiomics model based on magnetic resonance imaging in differentiating fibroblastic meningiomas from non-fibroblastic meningiomas.
Clinical, imaging, and postoperative pathologic data of 423 patients (128 fibroblastic meningiomas and 295 non-fibroblastic meningiomas) were randomly categorized into training (n = 296) and validation (n = 127) groups at a 7:3 ratio. The Selectpercentile and LASSO were used to selected the highly correlated features from 3376 radiomics features. Different classifiers were used to train and verify the model. The receiver operating characteristic curves, accuracy (ACC), sensitivity (SEN), and specificity (SPE) were drawn to evaluate the performance. The optimal radiomics model was selected. Calibration curves and decision curve analysis were used to verify the clinical utility and consistency of the nomogram constructed from the radiomics features and clinical factors.
Thirteen radiomics features were selected from contrast-enhanced T1-weighted imaging and T2-weighted imaging after dimensionality reduction. The prediction performance of random forest radiomics model is slightly lower than that of the clinical-radiomics model. The area under the curve, SEN, SPE, and ACC of the clinical-radiomics model training set were 0.836 (95% confidence interval, 0.795–0.878), 0.922, 0.583, and 0.686, respectively. The area under the curve, SEN, SPE, and ACC of the validation set were 0.756 (95% confidence interval, 0.660–0.846), 0.816, 0.596, and 0.661, respectively.
The diagnostic efficacy of the clinical-radiomics model of fibroblastic meningioma and non-fibroblastic meningioma was better than that of the radiomics prediction model alone and can be used as a potential tool for clinical surgical planning and evaluation of patient prognosis.
Meningioma grading based on positron emission tomography: A systematic review and meta-analysis
2023, World Neurosurgery: X
Meningiomas are the most common central nervous system tumor in adults. Knowledge of the tumor grade can guide optimal treatment timing and shape personalized follow-up strategies. Positron emission tomography (PET) has been utilized for the metabolic assessment of various intracranial space-occupying lesions. Herewith, we set out to evaluate the diagnostic accuracy of PET for the noninvasive assessment of meningioma's grade.
The Medline, Scopus and Cochrane databases were systematically searched in March 2022 for studies that evaluated the sensitivity and specificity of PET compared to the gold standard of histological diagnosis in the grading of meningiomas. Summary statistics will be calculated and scatter plots, summary curve from the HSROC model and posterior predictions by empirical Bayes estimates will be presented.
Five studies consisting of 242 patients with a total of 196 low-grade (Grade 1) and 46 high grade (Grade 2/3) meningiomas were included in our analysis. Three of the included studies used ¹⁸F-FDG, one study used ¹⁸F-FLT and one used(Whiting et al., 2011) 18 F-FET as PET tracers. The pooled sensitivity was 76% (95% CI: 52%–91%) and the pooled specificity was 89% (95% CI: 83%–93%). The diagnostic odds ratio was 27.17 (95% CI: 9.22–80.06), the positive likelihood ratio was 7.18 (95% CI: 4.54–11.34) and the negative likelihood ratio was 0.26 (95% CI: 0.11–0.61).
PET is a promising and viable option as a noninvasive imaging tool to differentiate the meningioma grades. However, currently it cannot overtake the gold standard of histological grade confirmation. More studies are required for further validation and refinement of this imaging technique and assessment of other radiotracers as well.
Sphenoid Wing Meningiomas with Secondary Cavernous Sinus Invasion: Surgical Results and Algorithm for Treatment at a Single Brazilian Center
2022, World Neurosurgery
Sphenoid wing meningiomas with cavernous sinus invasion (SWMCSI) are challenging tumors. The preservation of quality of life and cranial nerve function is one of the most relevant aspects of treating patients with SWMCSI.
A retrospective study was conducted for surgery performed between 2008 and 2021, including 36 patients presenting with SWMCSI. The data from surgical intervention, Simpson grade of resection, tumor location, and morbimortality related to the surgery was reviewed. We examined the medical records, operative reports, radiologic examinations, and follow-up information.
The group comprised 29 women and 7 men with an average age of 61 years (range, 31–87 years). The mean follow-up period was 75 months (range, 1–170 months). Simpson grade I and II resections were obtained in 80% of cases. The meningiomas were World Health Organization (WHO) grade 1 in 94% of cases, WHO grade 2 in 3%, and WHO grade 3 in 3%. The overall mortality was 5.5%. Permanent cranial nerve deficits occurred in 8% of cases, transient cranial nerve deficits in 22%, cerebrospinal fistula in 16.5%, and hemiparesis in 2.7%. The recurrence/regrowth rate was 14% during the follow-up period. The Karnofsky Performance Status 100 and 90 was 92%.
The surgical treatment of symptomatic SWMCSI is an effective treatment modality with low morbimortality and good long-term control of the disease. Visual impairment is the most common abnormality, affecting preoperative and postoperative quality of life of patients with SWMCSI. Training in the microsurgical laboratory is essential for safe surgical approaches in this area.
Targeting DNA Methyl Transferases with Decitabine in Cultured Meningiomas
2022, World Neurosurgery
Meningiomas are a common primary central nervous system tumor that lack a U.S. Food and Drug Administration–approved pharmacotherapy. Approximately 20%–35% of meningiomas are classified as higher grade with poor outcome, whereas patients with lower-grade meningiomas are known to have long-term neurologic deficits and reduced overall survival. Recent efforts to understand the epigenetic landscape of meningiomas have highlighted the importance of DNA methylation for predicting tumor outcomes and prognosis; therefore, inhibition of these pathways may present a viable therapy for these tumors.
In this study, we perform dose–response curves of decitabine, a DNA methyltransferase inhibitor, on patient-cultured tumors and meningioma cell lines.
Thirty total samples were evaluated, including 24 patient-cultured tumors and 6 established meningioma cell lines. Meningiomas were found to have a significant reduction in cell viability after decitabine treatment in a dose dependent manner. The effect was primarily driven by 11 of the 30 tumors in our cohort, or 36.7%. Decitabine significantly reduced cell viability across all grades, tumors from different sexes, recurrent and primary tumors, as well as tumors without a history of previous radiation. Surprisingly, our single radiation-induced tumor did demonstrate greater viability after decitabine treatment.
Our work has identified a potential drug candidate in decitabine for the treatment of meningiomas regardless of clinical subgroup. These data require further evaluation in preclinical models, and the conclusions based on clinical subgroups need to be evaluated in a larger cohort to achieve appropriate statistical power.
Expression of IL-6 and matrix metalloproteinases in a convexity meningiomas with hyperostosis: Case report
2022, Interdisciplinary Neurosurgery: Advanced Techniques and Case Management
Meningiomas are usually benign but can extend to their surroundings, infiltrating skeletal and brain structures. Skull invasion by meningiomas could be associated with adverse outcomes, including progression and recurrence. The molecular mechanisms regulating the invasive potential of these tumors are not well characterized. Here, we describe the clinical, imaging, and neuropsychological characteristics of a patient with a convexity fibrous meningioma invading the skull. Furthermore, we analyzed the tumoral expression of some molecular factors potentially implicated in bone invasion using immunohistochemistry. Our analysis reveals high expression of matrix metalloproteinase 1 (MMP-1), MMP-2, MMP-9, and interleukin 6 (IL-6) in the resected meningioma. Importantly, little brain expression of these factors was detected in public human tissue gene expression databases, nor a meningioma without hyperostosis that served as a control. Our study suggests a possible role for IL-6 and matrix-metalloproteinases in bone invasion by meningiomas that must be validated in larger cohorts.
Quality of Life Assessment in Patients with Surgically Treated Parasagittal Meningiomas
2024, Turkish Neurosurgery

View all citing articles on Scopus

View full text

Seemingly complete removal of histologically benign intracranial meningioma: Late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis

Abstract

Surg Neurol

Surg Neurol

Surg Neurol

The recurrence of intracranial meningiomas after surgical treatment

J Neurosurg

Histological sequences in the meningioma, with a consideration of the nature of the hyperostosis cranii

Arch pathol

Invading meningiomas of the sphenoid ridge

J Neurosurg

Morbidity, mortality, and quality of life following surgery for intracranial meningiomas

Introduction to stochastic processes in biostatistics

Prediction of recurrence in meningiomas after surgical treatment

Acta Neuropathol (Berl)

Meningiomas, their classification, regional behavior, life history, and end surgical results

Maximum utilization of the life-table method in analyzing survival

J Chron Dis

Bone formation and destruction in hyperostoses associated with meningiomas

J Neuropathol Exp Neurol